Table 3.
Cox regression analysis of variables associated with PFS and OS in the 308 patients treated with CAPTEM.
| Progression-free survival | Overall survival | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Gender (male vs. female) | 0.91 | 0.79-1.05 | .22 | 0.84 | 0.69-1.01 | .07 |
| Age (≤50 vs. > 50) | 1.17 | 0.87-1.57 | .29 | 1.99 | 1.32-3.00 | .001 |
| Comorbidities (yes vs. no) | 1.09 | 0.94-1.27 | .21 | 0.92 | 0.76-1.10 | .37 |
| PS (ECOG 0-1 vs. 2) | 0.97 | 0.77-1.21 | .79 | 0.75 | 0.58-0.97 | .03 |
| Site type (pancreas vs. others) | 0.88 | 0.66-1.17 | .39 | 0.87 | 0.60-1.26 | .46 |
| Ki- 67 (≤20% vs. 21%-55%) | 1.15 | 0.75-1.75 | .51 | 1.80 | 1.09-2.96 | .02 |
| Grade (1-2 vs. 3) | 1.24 | 0.81-1.88 | .30 | 1.54 | 0.92-2.57 | .09 |
| First-line therapy vs. subsequent therapies* | 0.80 | 0.69-0.93 | .003 | 0.72 | 0.60-0.88 | .001 |
| Prior surgery (curative) | 1.21 | 1.02-1.44 | .02 | 1.48 | 1.14-1.90 | .002 |
Bold values indicate statistically significant (P<0.05).
*Subsequent therapies include second “,third and more lines therapies”.